156 related articles for article (PubMed ID: 11193904)
1. In vitro antitumor activity of 9-nitro-camptothecin as a single agent and in combination with other antitumor drugs.
Bernacki RJ; Pera P; Gambacorta P; Brun Y; Greco WR
Ann N Y Acad Sci; 2000; 922():293-7. PubMed ID: 11193904
[TBL] [Abstract][Full Text] [Related]
2. In vitro sensitivity of human endometrial cancer cell lines to paclitaxel or irinotecan (CPT-11) in combination with other aniticancer drugs.
Hiramatsu HP; Kikuchi Y; Seto H; Nagata I
Anticancer Drugs; 2000 Aug; 11(7):573-8. PubMed ID: 11036961
[TBL] [Abstract][Full Text] [Related]
3. Synergistic antitumor activity of capecitabine in combination with irinotecan.
Cao S; Durrani FA; Rustum YM
Clin Colorectal Cancer; 2005 Jan; 4(5):336-43. PubMed ID: 15663838
[TBL] [Abstract][Full Text] [Related]
4. Synergistic antitumor activity of the novel SN-38-incorporating polymeric micelles, NK012, combined with 5-fluorouracil in a mouse model of colorectal cancer, as compared with that of irinotecan plus 5-fluorouracil.
Nakajima TE; Yasunaga M; Kano Y; Koizumi F; Kato K; Hamaguchi T; Yamada Y; Shirao K; Shimada Y; Matsumura Y
Int J Cancer; 2008 May; 122(9):2148-53. PubMed ID: 18196580
[TBL] [Abstract][Full Text] [Related]
5. Inhibitory effect of combined administration with CPT-11 and 5-fluorouracil in vitro and in vivo.
Satoh H; Ohtomo M; Ishikawa H; Kamma H; Ohtsuka M; Hasegawa S
Cancer Biochem Biophys; 1999 Jul; 17(1-2):59-67. PubMed ID: 10738902
[TBL] [Abstract][Full Text] [Related]
6. Metronomic 5-fluorouracil, oxaliplatin and irinotecan in colorectal cancer.
Fioravanti A; Canu B; Alì G; Orlandi P; Allegrini G; Di Desidero T; Emmenegger U; Fontanini G; Danesi R; Del Tacca M; Falcone A; Bocci G
Eur J Pharmacol; 2009 Oct; 619(1-3):8-14. PubMed ID: 19695243
[TBL] [Abstract][Full Text] [Related]
7. Effect of CPT-11 in combination with other anticancer agents in lung cancer cells.
Pei XH; Nakanishi Y; Takayama K; Bai F; Kawasaki M; Tsuruta N; Mizuno K; Hara N
Anticancer Drugs; 1997 Mar; 8(3):231-7. PubMed ID: 9095327
[TBL] [Abstract][Full Text] [Related]
8. Sequence-dependent growth inhibition and DNA damage formation by the irinotecan-5-fluorouracil combination in human colon carcinoma cell lines.
Mans DR; Grivicich I; Peters GJ; Schwartsmann G
Eur J Cancer; 1999 Dec; 35(13):1851-61. PubMed ID: 10674003
[TBL] [Abstract][Full Text] [Related]
9. Irinophore C™, a lipid nanoparticulate formulation of irinotecan, improves vascular function, increases the delivery of sequentially administered 5-FU in HT-29 tumors, and controls tumor growth in patient derived xenografts of colon cancer.
Neijzen R; Wong MQ; Gill N; Wang H; Karim T; Anantha M; Strutt D; Waterhouse D; Bally MB; Tai IT; Ng SS; Yapp DT
J Control Release; 2015 Feb; 199():72-83. PubMed ID: 25497312
[TBL] [Abstract][Full Text] [Related]
10. Sequential treatment with SN-38 followed by 5-fluorouracil shows synergistic cytotoxic activity in small cell lung cancer cells.
Takeda K; Suyama H; Igishi T; Shigeoka Y; Matsumoto S; Yamasaki A; Hashimoto K; Sumikawa T; Morita M; Ueda Y; Shimizu E
Oncol Rep; 2008 Apr; 19(4):945-51. PubMed ID: 18357380
[TBL] [Abstract][Full Text] [Related]
11. In vitro schedule-dependent interaction between paclitaxel and SN-38 (the active metabolite of irinotecan) in human carcinoma cell lines.
Kano Y; Akutsu M; Tsunoda S; Mori K; Suzuki K; Adachi KI
Cancer Chemother Pharmacol; 1998; 42(2):91-8. PubMed ID: 9654107
[TBL] [Abstract][Full Text] [Related]
12. [Lidamycin inhibits the proliferation of HERG K+ channel highly expressing cancer cells and shows synergy with anticancer drugs].
Shang BY; Shang Y; Zhen YS; Chen SZ
Yao Xue Xue Bao; 2011 Nov; 46(11):1321-5. PubMed ID: 22260022
[TBL] [Abstract][Full Text] [Related]
13. Schedule-dependent synergism between raltitrexed and irinotecan in human colon cancer cells in vitro.
Aschele C; Baldo C; Sobrero AF; Debernardis D; Bornmann WG; Bertino JR
Clin Cancer Res; 1998 May; 4(5):1323-30. PubMed ID: 9607593
[TBL] [Abstract][Full Text] [Related]
14. Molecular mechanisms of sequence-dependent antitumor effects of SN-38 and 5-fluorouracil combination therapy against colon cancer cells.
Torigoe S; Ogata Y; Matono K; Shirouzu K
Anticancer Res; 2009 Jun; 29(6):2083-9. PubMed ID: 19528468
[TBL] [Abstract][Full Text] [Related]
15. Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin.
Zeghari-Squalli N; Raymond E; Cvitkovic E; Goldwasser F
Clin Cancer Res; 1999 May; 5(5):1189-96. PubMed ID: 10353756
[TBL] [Abstract][Full Text] [Related]
16. Irinotecan overcomes the resistance to 5-fluorouracil in human colon cancer xenografts by down-regulation of intratumoral thymidylate synthase.
Fukushima M; Sakamoto K; Ohshimo H; Nakagawa F; Taguchi T
Oncol Rep; 2010 Oct; 24(4):835-42. PubMed ID: 20811661
[TBL] [Abstract][Full Text] [Related]
17. Advantage of combined treatment of CPT-11 and 5-fluorouracil.
Matsuoka H; Yano K; Takiguchi S; Kono A; Seo Y; Saito T; Tomoda H
Anticancer Res; 1995; 15(4):1447-52. PubMed ID: 7654033
[TBL] [Abstract][Full Text] [Related]
18. Angiocytotoxic therapy in human non-small cell lung cancer cell lines--advantage of combined effects of TNP-470 and SN-38.
Satoh H; Ishikawa H; Fujimoto M; Fujiwara M; Yamashita YT; Yazawa T; Ohtsuka M; Hasegawa S; Kamma H
Acta Oncol; 1998; 37(1):85-90. PubMed ID: 9572659
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity of new combination chemotherapy with irinotecan hydrochloride and nedaplatin against human cervical cancer cell lines.
Yamamoto K; Iwahana M; Kumazawa E; Kakihata K; Abe K; Hirano F; Tohgo A; Hoshiai H; Noda K
Oncol Rep; 2003; 10(3):593-8. PubMed ID: 12684629
[TBL] [Abstract][Full Text] [Related]
20. Thrombospondin-1 plus irinotecan: a novel antiangiogenic-chemotherapeutic combination that inhibits the growth of advanced human colon tumor xenografts in mice.
Allegrini G; Goulette FA; Darnowski JW; Calabresi P
Cancer Chemother Pharmacol; 2004 Mar; 53(3):261-6. PubMed ID: 14658007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
